Drug intelligence / Profile preview

FAD286

Development stage: Preclinical
Lead developer: Novartis
Modality: Small Molecules
Administration: Subcutaneous, Oral (research Context Varies)

Overview

FAD286 is an aldosterone synthase inhibitor, specifically targeting the enzyme Cytochrome P450 11B2 (CYP11B2). It is primarily researched for its potential in treating conditions related to excessive aldosterone production, such as hyperaldosteronism. FAD286 has shown efficacy in improving glucose tolerance and reducing atherosclerosis in animal models[1][7]. However, it has adverse effects during intestinal inflammation, exacerbating inflammation and reducing body weight gain[3][5].

Other names: FAD-286[8]

Targets

CYP11B2 (Cytochrome P450 11B2)CYP19A1 (Aromatase)

Beyond the preview

Go deeper on FAD286.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FAD286.

Explore the full profile